^
Association details:
| Biomarker: | BAP1 deletion + TMB-L + PD-L1 expression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
Published date:
04/05/2022
Excerpt:
We present a case of a patient with BAP1 cancer syndrome who developed a metastatic breast cancer with loss of BAP1 demonstrated on immunohistochemistry...In addition, tumor tissue sequencing identified a concurrent somatic variant in BAP1 (partial deletion of exon 12) and a low tumor mutational burden. As her triple negative tumor was shown to be PD-L1 positive, the patient was treated with combination of atezolizumab and nab-paclitaxel. She had a complete and sustained response to immunotherapy even after discontinuation of nab-paclitaxel.
Secondary therapy:
albumin-bound paclitaxel
DOI:
https://doi.org/10.1007/s12282-022-01354-0
